Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lung Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Thymoma 1Stomach Neoplasms 1Rectal Neoplasms 1Metastatic Small Intestinal Adenocarcinoma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 21Fluorouracil 20Leucovorin 19Capecitabine 18Irinotecan 13Radiotherapy 8Bevacizumab 7Cetuximab 6Folfox protocol 4cediranib 2Radiation 2Psychiatric Rehabilitation 2Octreotide 2Cisplatin 2Chemoradiotherapy 2tipifarnib 1pertuzumab 1olaparib 1mercaptoundecahydrododecaborate 1eniluracil 1durvalumab 1brivanib 1alpha-Tocopherol 1Watchful Waiting 1Vitamin E 1Trastuzumab 1Tegafur 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Standard of Care 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Rectal Neoplasms × Ramucirumab × Clear all
NCT01079780 2023-06-28

Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Eastern Cooperative Oncology Group

Phase 2 Completed
136 enrolled 13 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡